Preparations for the launch of IBP-9414 continue, with FDA review underway and initial feedback expected in September 2025. Operating losses and cash outflows have narrowed year-over-year, and capital is sufficient through the marketing authorization process.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.